Spero Therapeutics, Inc. (SPRO)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
1.15 USD
-0.03
(-2.542%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 10:49 a.m. EDT
The long-term outlook remains solid despite the recent price correction, driven by a robust balance sheet and a massive $105 million royalty financing deal that secures the pipeline. The company has successfully navigated a severe multi-year decline, with the latest year showing an explosive 81% recovery, indicating the worst is likely behind it. However, the short-term chart is currently broken, trading well below its 200-day average, and the statistical forecast leans negative due to lingering volatility. Crucially, there is no dividend to provide income, making this a pure speculative play on the immunology drug's success. The heavy put writing in the options chain confirms that the market is pricing in significant downside risk in the immediate term, creating a tense environment where the strong fundamentals are fighting against a cautious, defensive sentiment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.127426 |
| AutoARIMA | 0.258556 |
| MSTL | 0.260997 |
| AutoETS | 0.266681 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 0.15 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.177 |
| Excess Kurtosis | -0.30 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.622 |
| Revenue per Share | 0.825 |
| Market Cap | 66,970,052 |
| Trailing P/E | 8.21 |
| Forward P/E | -1.04 |
| Beta | 1.50 |
| Profit Margins | 15.71% |
| Website | https://sperotherapeutics.com |
As of Oct. 10, 2026, 10:49 a.m. EDT: Speculators are heavily positioned for downside protection, with massive open interest in out-of-the-money puts at the $2.50 strike compared to negligible call volume at similar strikes. This asymmetry suggests a 'long gamma' hedging strategy where traders are betting on volatility or protecting against a drop below the $1.00 floor, rather than a bullish breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.5 |
| Address1 | 675 Massachusetts Avenue |
| Address2 | 14th Floor |
| All Time High | 23.639 |
| All Time Low | 0.505 |
| Ask | 1.17 |
| Ask Size | 4 |
| Average Daily Volume10 Day | 592,700 |
| Average Daily Volume3 Month | 1,197,485 |
| Average Volume | 1,197,485 |
| Average Volume10Days | 592,700 |
| Beta | 1.498 |
| Bid | 0.8496 |
| Bid Size | 2 |
| Book Value | 0.76 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.15 |
| Current Ratio | 6.121 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.2027 |
| Day Low | 1.15 |
| Debt To Equity | 4.622 |
| Display Name | Spero Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,568,400 |
| Earnings Call Timestamp Start | 1,786,568,400 |
| Earnings Timestamp | 1,786,564,800 |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda Margins | 0.0 |
| Enterprise To Revenue | 0.388 |
| Enterprise Value | 18,239,052 |
| Eps Forward | -1.11 |
| Eps Trailing Twelve Months | 0.14 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.2011 |
| Fifty Day Average Change | -0.051100016 |
| Fifty Day Average Change Percent | -0.042544346 |
| Fifty Two Week Change Percent | -50.0 |
| Fifty Two Week High | 3.08 |
| Fifty Two Week High Change | -1.93 |
| Fifty Two Week High Change Percent | -0.6266234 |
| Fifty Two Week Low | 1.08 |
| Fifty Two Week Low Change | 0.06999993 |
| Fifty Two Week Low Change Percent | 0.064814754 |
| Fifty Two Week Range | 1.08 - 3.08 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,509,629,400,000 |
| Float Shares | 47,099,746 |
| Forward Eps | -1.11 |
| Forward P E | -1.036036 |
| Free Cashflow | 28,848,500 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 25 |
| Fullday Change | -0.029999971 |
| Fullday Change Percent | -2.5423706 |
| Fullday Price | 1.15 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.56312 |
| Gross Profits | 26,465,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.22662 |
| Held Percent Institutions | 0.18254 |
| Implied Shares Outstanding | 58,234,827 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Spero Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 66,970,052 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_240573619 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 7,383,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 73,667,056 |
| Number Of Analyst Opinions | 2 |
| Open | 1.19 |
| Operating Cashflow | 19,580,000 |
| Operating Margins | 0.14069 |
| Payout Ratio | 0.0 |
| Phone | 857 242 1600 |
| Previous Close | 1.18 |
| Price Hint | 4 |
| Price To Book | 1.5131578 |
| Price To Sales Trailing12 Months | 1.4249856 |
| Profit Margins | 0.1571 |
| Quick Ratio | 6.027 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.03 |
| Regular Market Change Percent | -2.54237 |
| Regular Market Day High | 1.2027 |
| Regular Market Day Low | 1.15 |
| Regular Market Day Range | 1.15 - 1.2027 |
| Regular Market Open | 1.19 |
| Regular Market Previous Close | 1.18 |
| Regular Market Price | 1.15 |
| Regular Market Time | 1,791,921,600 |
| Regular Market Volume | 272,491 |
| Return On Assets | 0.07194 |
| Return On Equity | 0.19169001 |
| Revenue Per Share | 0.825 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 58,234,827 |
| Shares Percent Shares Out | 0.0136 |
| Shares Short | 794,509 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 1,210,417 |
| Short Name | Spero Therapeutics, Inc. |
| Short Percent Of Float | 0.0164 |
| Short Ratio | 1.06 |
| Source Interval | 15 |
| State | MA |
| Symbol | SPRO |
| Target High Price | 6.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 5.0 |
| Target Median Price | 5.0 |
| Total Cash | 50,774,000 |
| Total Cash Per Share | 0.872 |
| Total Debt | 2,043,000 |
| Total Revenue | 46,997,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.14 |
| Trailing P E | 8.214286 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.0741 |
| Two Hundred Day Average Change | -0.92410004 |
| Two Hundred Day Average Change Percent | -0.44554266 |
| Type Disp | Equity |
| Volume | 272,491 |
| Website | https://sperotherapeutics.com |
| Zip | 2,139 |